ALNY
Price
$261.87
Change
-$8.16 (-3.02%)
Updated
Apr 1, 02:28 PM (EDT)
Capitalization
34.75B
30 days until earnings call
IONS
Price
$27.53
Change
-$2.64 (-8.75%)
Updated
Apr 1, 03:16 PM (EDT)
Capitalization
4.95B
29 days until earnings call
Ad is loading...

ALNY vs IONS

Header iconALNY vs IONS Comparison
Open Charts ALNY vs IONSBanner chart's image
Alnylam Pharmaceuticals
Price$261.87
Change-$8.16 (-3.02%)
Volume$800
Capitalization34.75B
Ionis Pharmaceuticals
Price$27.53
Change-$2.64 (-8.75%)
Volume$3.6K
Capitalization4.95B
ALNY vs IONS Comparison Chart
Loading...
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALNY vs. IONS commentary
Apr 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALNY is a Hold and IONS is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 01, 2025
Stock price -- (ALNY: $270.02 vs. IONS: $30.17)
Brand notoriety: ALNY and IONS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALNY: 131% vs. IONS: 123%
Market capitalization -- ALNY: $34.75B vs. IONS: $4.95B
ALNY [@Biotechnology] is valued at $34.75B. IONS’s [@Biotechnology] market capitalization is $4.95B. The market cap for tickers in the [@Biotechnology] industry ranges from $304.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALNY’s FA Score shows that 1 FA rating(s) are green whileIONS’s FA Score has 0 green FA rating(s).

  • ALNY’s FA Score: 1 green, 4 red.
  • IONS’s FA Score: 0 green, 5 red.
According to our system of comparison, ALNY is a better buy in the long-term than IONS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALNY’s TA Score shows that 5 TA indicator(s) are bullish while IONS’s TA Score has 4 bullish TA indicator(s).

  • ALNY’s TA Score: 5 bullish, 5 bearish.
  • IONS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ALNY is a better buy in the short-term than IONS.

Price Growth

ALNY (@Biotechnology) experienced а -7.11% price change this week, while IONS (@Biotechnology) price change was -9.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.00%. For the same industry, the average monthly price growth was -12.28%, and the average quarterly price growth was -11.17%.

Reported Earning Dates

ALNY is expected to report earnings on May 01, 2025.

IONS is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Biotechnology (-8.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALNY($34.7B) has a higher market cap than IONS($4.95B). ALNY YTD gains are higher at: 14.751 vs. IONS (-13.701). ALNY has higher annual earnings (EBITDA): -178.85M vs. IONS (-353.72M). ALNY has more cash in the bank: 2.7B vs. IONS (2.3B). ALNY has less debt than IONS: ALNY (1.3B) vs IONS (1.42B). ALNY has higher revenues than IONS: ALNY (2.25B) vs IONS (705M).
ALNYIONSALNY / IONS
Capitalization34.7B4.95B701%
EBITDA-178.85M-353.72M51%
Gain YTD14.751-13.701-108%
P/E RatioN/AN/A-
Revenue2.25B705M319%
Total Cash2.7B2.3B117%
Total Debt1.3B1.42B91%
FUNDAMENTALS RATINGS
ALNY vs IONS: Fundamental Ratings
ALNY
IONS
OUTLOOK RATING
1..100
2217
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
96
Overvalued
PROFIT vs RISK RATING
1..100
20100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
4077
P/E GROWTH RATING
1..100
10059
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IONS's Valuation (96) in the Biotechnology industry is in the same range as ALNY (99). This means that IONS’s stock grew similarly to ALNY’s over the last 12 months.

ALNY's Profit vs Risk Rating (20) in the Biotechnology industry is significantly better than the same rating for IONS (100). This means that ALNY’s stock grew significantly faster than IONS’s over the last 12 months.

IONS's SMR Rating (98) in the Biotechnology industry is in the same range as ALNY (100). This means that IONS’s stock grew similarly to ALNY’s over the last 12 months.

ALNY's Price Growth Rating (40) in the Biotechnology industry is somewhat better than the same rating for IONS (77). This means that ALNY’s stock grew somewhat faster than IONS’s over the last 12 months.

IONS's P/E Growth Rating (59) in the Biotechnology industry is somewhat better than the same rating for ALNY (100). This means that IONS’s stock grew somewhat faster than ALNY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALNYIONS
RSI
ODDS (%)
Bearish Trend 2 days ago
78%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
66%
Bullish Trend 2 days ago
63%
Momentum
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
68%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
72%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
68%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
70%
Advances
ODDS (%)
Bullish Trend 9 days ago
75%
Bullish Trend 9 days ago
62%
Declines
ODDS (%)
Bearish Trend 7 days ago
67%
Bearish Trend 2 days ago
70%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
77%
Aroon
ODDS (%)
Bearish Trend 2 days ago
67%
Bullish Trend 2 days ago
61%
View a ticker or compare two or three
Ad is loading...
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CAPCX8.57N/A
N/A
Federated Hermes Capital Income C
BMRRX30.88N/A
N/A
BlackRock Mid-Cap Growth Equity R
TFIFX42.53N/A
N/A
T. Rowe Price Financial Services I
PGKCX21.44N/A
N/A
PGIM Jennison Technology C
FEGKX13.22N/A
N/A
Fidelity Equity Growth K6